Abstract:ABSTRACT Staphylococcus aureus is an important human pathogen in both community and hospital settings that often causes persistent and recurrent infections. The continuous emergence of multidrug-resistant strains and the lag in antibiotic development make the treatment of S. aureus more challenging. The biofilm formation of S. aureus is an important reason for persistent infection. In this study, we demonstrated that a small-molecule compound S-342-3 can effectively inhibit the biofilm formation of S. aureus . The crystal violet semi-quantitative assays revealed that at a sub-minimum inhibitory concentration of 4 μg/mL, S-342-3 reduced S. aureus biofilm mass by 57.43%, 52.14%, and 25.49%. Using confocal laser scanning microscopy, we observed that the biofilm was more incompact and less uniform upon the treatment of S-342-3. At a sub-inhibitory concentration (4 μg/mL), the S-342-3 can effectively reduce the production of polysaccharide intercellular adhesin (PIA) and suppress the initial adhesion of cells in the biofilm. Consistently, the results of RT-qPCR revealed that the expression of genes associated with biofilm formation was downregulated by S-342-3 ( P < 0.05). However, we found that treatment with S-342-3 resulted in a significant decrease in the expression of global regulatory genes agrA and sarA ( P < 0.05), which play a key role in promoting cell surface attachment and PIA production in S. aureus biofilms. Also importantly, we experimentally proved that the S-342-3 was not toxic to A549 alveolar epithelial cells and the Galleria mellonella larvae. Collectively, these results suggest that the S-342-3 may be a promising anti-biofilm drug candidate with excellent biosafety, which can be further explored for its practical application in health care. IMPORTANCE Biofilms are an important virulence factor in Staphylococcus aureus and are characterized by a structured microbial community consisting of bacterial cells and a secreted extracellular polymeric matrix. Inhibition of biofilm formation is an effective measure to control S. aureus infection. Here, we have synthesized a small molecule compound S-342-3, which exhibits potent inhibition of biofilm formation in both MRSA and MSSA. Further investigations revealed that S-342-3 exerts inhibitory effects on biofilm formation by reducing the production of polysaccharide intercellular adhesin and preventing bacterial adhesion. Our study has confirmed that the inhibitory effect of S-342-3 on biofilm is achieved by downregulating the expression of genes responsible for biofilm formation. In addition, S-342-3 is non-toxic to Galleria mellonella larvae and A549 cells. Consequently, this study demonstrates the efficacy of a biologically safe compound S-342-3 in inhibiting biofilm formation in S. aureus, thereby providing a promising antibiofilm agent for further research.

Physicochemical properties and formulation development of a novel compound inhibiting Staphylococcus aureus biofilm formation

Novel Fluorinated Pyrrolomycins As Potent Anti-Staphylococcal Biofilm Agents: Design, Synthesis, Pharmacokinetics and Antibacterial Activities.

A novel small-molecule compound S-342-3 effectively inhibits the biofilm formation of Staphylococcus aureus

Small-Molecule Compound SYG-180-2-2 to Effectively Prevent the Biofilm Formation of Methicillin-Resistant Staphylococcus aureus

Insights into small-molecule compound CY-158-11 antibacterial activity against Staphylococcus aureus

Antibiofilm Activity of Small-Molecule ZY-214-4 Against Staphylococcus Aureus

Deciphering the dynamics of methicillin-resistant Staphylococcus aureus biofilm formation: from molecular signaling to nanotherapeutic advances

Antimicrobial and anti-biofilm activity of a thiazolidinone derivative against Staphylococcus aureus in vitro and in vivo

CPF-C1 Analog with Effective Antimicrobial and Antibiofilm Activities Against Staphylococcus Aureus Including MRSA

Staphylococcus Aureus Biofilm: Formulation, Regulatory, and Emerging Natural Products-Derived Therapeutics

Lipase and pH-responsive diblock copolymers featuring fluorocarbon and carboxyl betaine for methicillin-resistant staphylococcus aureus infections

Inhibition of Growth and Biofilm Formation in Staphylococcus Aureus by LLY-507

Synthesis and antibiofilm evaluation of N-acyl-2-aminopyrimidine derivatives against Acinetobacter baumannii

Preparation and Pharmacokinetic Characterization of an Anti-Virulence Compound Nanosuspensions

Novel small-molecule compound YH7 inhibits the biofilm formation of Staphylococcus aureus in a sarX-dependent manner

Bromophenazine derivatives with potent inhibition, dispersion and eradication activities against Staphylococcus aureus biofilms

Antimicrobial activity of 1,3,4-oxadiazole derivatives against planktonic cells and biofilm of Staphylococcus aureus.

Charge Adaptive Phytochemical-based Nanoparticles for Eradication of Methicillin-Resistant Staphylococcus Aureus Biofilms

Enantiomeric Glycosylated Cationic Block Co-Beta-peptides Eradicate Staphylococcus Aureus Biofilms and Antibiotic-Tolerant Persisters.

Antibacterial And Anti-Biofilm Activities Of Thiazolidione Derivatives Against Clinical Staphylococcus Strains

Chromone Derivatives CM3a Potently Eradicate <i>Staphylococcus aureus</i> Biofilms by Inhibiting Cell Adherence